Our Pricing

Private Mounjaro vs Ozempic Cost: Skip NHS Waiting

Understanding the private Mounjaro vs Ozempic cost UK landscape is essential when choosing your weight loss treatment. At Cured Pharmacy, Mounjaro (tirzepatide) is available from £135.00 with transparent upfront pricing, free clinical consultation by UK prescribers, and next-day discreet delivery across the UK.

Mounjaro vs Ozempic: How They Compare for Weight Loss

Mounjaro contains tirzepatide, the UK's first dual GIP/GLP-1 receptor agonist, whilst Ozempic contains semaglutide, a single GLP-1 receptor agonist originally licensed for type 2 diabetes management [1]. Both medications work by mimicking natural hormones that regulate appetite and blood sugar, but tirzepatide's dual-action mechanism produces notably different clinical outcomes.

In head-to-head clinical trials, tirzepatide demonstrated superior weight reduction compared to semaglutide. The SURPASS-2 trial showed patients on the highest tirzepatide dose (15mg) achieved an average 15.7kg weight loss over 40 weeks, compared to 6.7kg with semaglutide 1mg [1]. For weight management specifically, the SURMOUNT-1 trial recorded up to 22.5% total body weight reduction with tirzepatide over 72 weeks [2].

Whilst Ozempic remains licensed primarily for type 2 diabetes in the UK, many prescribers have used it off-label for weight management. However, Mounjaro received MHRA approval specifically for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities, making it the clinically preferred choice for dedicated weight loss programmes [3].

Private Mounjaro vs Ozempic Cost UK: What You'll Actually Pay

Private prescription costs vary significantly across UK pharmacies, but transparency remains crucial when comparing options. At Cured Pharmacy, Mounjaro pricing starts from £135.00 per pen, with the exact cost determined by your prescribed dose following clinical assessment by a UK-registered prescriber.

Ozempic pricing through private channels typically reflects similar market positioning, though availability has been affected by ongoing supply constraints across the UK. It's worth noting that Ozempic's primary licence remains for diabetes management, whilst Mounjaro holds specific weight management approval from the MHRA, which may influence prescriber recommendations during your consultation.

Your total treatment cost depends on several factors: your starting dose, titration schedule, maintenance dose, and treatment duration. Most patients begin on lower doses and gradually increase over 8-12 weeks to minimise gastrointestinal side effects. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures all prescriptions follow NICE guidance and MHRA-approved dosing schedules.

What's Included in Your Cured Pharmacy Price

Every Mounjaro prescription from Cured Pharmacy includes free clinical consultation with a UK-registered prescriber (typically completed in under 3 minutes), genuine UK-licensed medication dispensed from our GPhC-registered pharmacy (9012511), discreet packaging with no pharmacy branding, and next-day delivery across the UK. There are no hidden consultation fees, membership charges, or surprise costs at checkout—the price you see is the price you pay.

Clinical Efficacy: Which Treatment Delivers Better Results?

The SURPASS clinical trial programme provides the most robust comparison between tirzepatide and semaglutide for weight management outcomes. In SURPASS-2, participants taking tirzepatide 15mg achieved mean weight reductions of 15.7kg, compared to 6.7kg with semaglutide 1mg—representing more than double the weight loss over 40 weeks [1].

For dedicated weight management, the SURMOUNT-1 trial examined tirzepatide in adults without diabetes but with obesity or overweight with comorbidities. Participants on the 15mg dose achieved an average 22.5% total body weight reduction over 72 weeks, with 63% of participants losing at least 20% of their body weight [2]. These results significantly exceed those seen in the STEP trials for semaglutide, where the highest responders averaged 14.9% weight loss [4].

Beyond weight reduction, both medications demonstrate improvements in cardiovascular risk markers, including blood pressure, lipid profiles, and inflammatory markers. However, tirzepatide's dual-receptor mechanism may offer additional metabolic benefits, particularly for patients with insulin resistance or prediabetes [1]. Your UK prescriber will assess your individual metabolic profile to determine which treatment aligns best with your clinical needs.

Side Effect Profiles and Tolerability

Both tirzepatide and semaglutide share similar side effect profiles, predominantly gastrointestinal symptoms including nausea, diarrhoea, vomiting, and constipation [1][2]. These effects are typically most pronounced during dose escalation and tend to diminish over time. In clinical trials, discontinuation rates due to adverse events were comparable between the two medications, ranging from 4-7% [1][4]. Gradual dose titration, as recommended in MHRA guidance, significantly improves tolerability and helps patients adapt to treatment.

Who Can Use Mounjaro vs Ozempic in the UK?

Mounjaro is licensed in the UK for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease [3]. The medication should be used alongside a reduced-calorie diet and increased physical activity as part of a comprehensive weight management programme.

Ozempic's UK licence covers type 2 diabetes management, though some prescribers may consider it for weight management in specific clinical scenarios. However, with Mounjaro now holding dedicated weight loss approval and demonstrating superior efficacy in trials, it has become the preferred first-line option for most patients seeking private weight management treatment [1][3].

Certain medical conditions preclude the use of GLP-1 receptor agonists, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, previous serious hypersensitivity to tirzepatide or semaglutide, and diabetic ketoacidosis. Pregnant or breastfeeding women should not use these medications. Your UK prescriber will conduct a thorough medical assessment to ensure treatment safety and suitability.

How to Start Private Mounjaro Treatment at Cured Pharmacy

Beginning your weight loss journey with Mounjaro involves a straightforward three-step process designed to ensure clinical safety whilst minimising delays. First, complete our free online consultation—a comprehensive medical questionnaire typically completed in under 3 minutes that covers your medical history, current medications, weight loss goals, and any contraindications.

A UK-registered prescriber from our clinical team reviews your consultation within hours, not days. If Mounjaro is clinically appropriate for you, they'll issue a private prescription specifying your starting dose and titration schedule. If tirzepatide isn't suitable, they may recommend alternative treatments such as Wegovy (semaglutide) or Saxenda (liraglutide), both available through Cured Pharmacy with the same transparent pricing model.

Once your prescription is approved, our GPhC-registered pharmacy (9012511) dispenses your medication and arranges next-day delivery in discreet, unbranded packaging. You'll receive full instructions on injection technique, storage requirements, dose escalation schedule, and what to expect during your first weeks of treatment. Our pharmacist team remains available via phone (+44 116 4646009) for any questions throughout your treatment journey.

Ongoing Support and Prescription Renewals

Weight management with Mounjaro is not a short-term intervention—clinical trials demonstrate optimal results with sustained treatment over 12-18 months or longer [2]. Cured Pharmacy provides ongoing prescription renewals with regular clinical reviews to monitor your progress, adjust dosing as needed, and ensure continued treatment safety. Your UK prescriber will assess weight loss trends, side effect management, and whether treatment continuation remains clinically appropriate at each renewal point.

Alternative Weight Loss Treatments Available at Cured Pharmacy

Whilst Mounjaro represents the most efficacious option in current clinical trials, several alternative treatments may be more suitable depending on your medical history, budget, and treatment preferences. Wegovy (semaglutide) offers once-weekly injections with proven weight loss outcomes from the STEP trial programme, demonstrating average reductions of 14.9% total body weight over 68 weeks [4].

Saxenda (liraglutide) provides a daily injection option for patients who prefer more frequent dosing or have previously responded well to liraglutide. Though requiring daily administration, Saxenda remains a well-established treatment with extensive real-world safety data. For patients seeking non-injectable options, Orlistat (available as generic, Xenical, or Alli formulations) works through a different mechanism by reducing dietary fat absorption in the gastrointestinal tract.

Your choice between these treatments should be guided by clinical factors rather than cost alone. During your consultation, our UK prescribers consider your medical history, previous weight loss attempts, injection tolerance, lifestyle factors, and treatment goals to recommend the most appropriate option. All prescription weight loss medications available through Cured Pharmacy are genuine UK-licensed products dispensed from our registered pharmacy, ensuring quality and safety regardless of which treatment you're prescribed.

Combining Medication with Lifestyle Changes

No weight loss medication works effectively in isolation—MHRA approval for Mounjaro, Wegovy, and Saxenda all specify use alongside reduced-calorie diet and increased physical activity [3]. Clinical trials demonstrating significant weight loss outcomes included structured lifestyle intervention programmes. Your prescriber may recommend working with a registered dietitian or weight management specialist to optimise your results and develop sustainable behavioural changes that extend beyond medication treatment.

Scientific References

1. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 398(10295), 64–77. https://doi.org/10.1016/S0140-6736(21)01324-6
2. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/14037
4. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, dietary modifications, and lifestyle changes. Clinical trial data represents average outcomes and does not guarantee individual results.